The therapeutic potential of the EIF4A inhibitor eFT226 has been investigated in B cell lymphoma and Burkitt lymphoma models through the coordinated translational inhibition of oncogenic drivers and transcription factors [35]. This evidence concerns the gene EIF4A1 and B-cell non-Hodgkin lymphoma.